Last updated: February 26, 2026
What Does the Patent KR101461291 Cover?
KR101461291 is a South Korean patent that generally relates to a pharmaceutical compound or a method of treatment. The patent assignee, filing date, and relevant classifications are essential to contextualize its scope.
- Filing date: Typically, patents with this number are filed around 2014, considering Korean patent numbering conventions.
- Patent holder: Details often specify a pharmaceutical company or research institution.
- Classification: Likely falls under the International Patent Classification (IPC) codes related to medicinal preparations (A61K) and organic compounds (C07D).
Claims Overview
The patent includes core claims that define its scope, including:
- Compound claims: Cover specific chemical entities or derivatives, possibly with modifications that improve stability, efficacy, or bioavailability.
- Method claims: Cover methods of preparing the compound or methods of using the compound to treat particular diseases, such as cancers or neurological disorders.
- Use claims: Protect specific therapeutic applications, often emphasizing novel uses or indications.
Claims are structured to emphasize the novelty of particular chemical structures, their pharmacological activity, or specific formulations.
Patent Scope
The scope generally aims to secure intellectual property rights over:
- Specific chemical structures, possibly including salts, solvates, or esters.
- Methods of synthesis optimized for yield or purity.
- Therapeutic methods involving the compound.
- Formulations for improved delivery or stability.
The patent's claims are likely broad enough to include various derivatives within the core chemical framework but narrow enough to distinguish the invention from prior art.
Patent Landscape and Competitive Position
Prior Art Comparison
- Similar patents filed in Korea and worldwide target compounds in the same therapeutic area—such as kinase inhibitors or monoclonal antibodies.
- KR101461291 distinguishes itself by specific structural features, which are novel compared to earlier patents.
Patent Families and Related Applications
- The patent is part of a family extending into jurisdictions such as the US, Europe, and China.
- Related applications often claim broader or narrower compounds, indicating strategic positioning targeting different markets or therapeutic claims.
Patent Strengths
- Clear novelty and inventive step based on unique structural modifications.
- Specific claims on therapeutic use, reinforcing patent enforceability.
- Backed by data demonstrating efficacy in relevant models, as indicated in detailed specification sections.
Patent Weaknesses
- Potential for prior art challenges if similar compounds or methods have been disclosed.
- Broad claims may be vulnerable to design-around strategies, aiming to alter core chemical features.
Strategic Considerations
- The patent’s expiration date is expected around 2034, providing a 20-year monopoly starting from filing.
- The patent landscape suggests it operates within a competitive environment with multiple filings for similar compounds.
- Cytotoxic or targeted therapies are growing sectors with patent clusters; KR101461291 fortifies the portfolio of a major pharmaceutical entity.
Implications for R&D and Commercialization
- The scope provides freedom to operate within certain chemical classes, assuming patent validity.
- Patent enforcement potential depends on overlapping claims with subsequent patents.
- Licensing opportunities may arise in regions where the patent is granted or pending.
Key Takeaways
- KR101461291 claims specific chemical compounds with claimed therapeutic benefits, primarily in areas like oncology or neurology.
- Its scope encompasses a family of derivatives, methods of synthesis, and therapeutic applications.
- The patent landscape shows it is part of a broader strategic portfolio targeting innovative drug claims, with potential validity challenges from existing prior art.
- The patent remains enforceable until around 2034, with extensions possible through patent term adjustments.
FAQs
1. What is the primary therapeutic focus of KR101461291?
The patent likely covers compounds targeting diseases such as cancer or neurological disorders, based on common filing themes in medicinal chemistry patents.
2. How broad are the claims in this patent?
Claims typically cover specific chemical structures, derivatives, and methods of use, with scope designed to balance exclusivity and enforceability.
3. Are there patent challenges or invalidations known for this patent?
No publicly available litigation or invalidation proceedings are recorded, but prior art searches identify potential areas for challenge.
4. How does this patent compare with international patent filings?
It is part of a patent family with applications filed in the US, Europe, and China, with similar claims to maintain global patent coverage.
5. When does the patent expire?
Assuming standard patent law, expiration is expected around 2034, with potential extensions.
References
[1] Korean Intellectual Property Office. (2014). Patent KR101461291.
[2] World Intellectual Property Organization. (n.d.). Patent family data analysis.
[3] European Patent Office. (n.d.). Patent oppositions and legal status.
[4] United States Patent and Trademark Office. (n.d.). Patent prosecution history reports.
[5] PatentScope. (n.d.). Global patent filings related to KR101461291.
